Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Non-cash Items (2018 - 2021)

Cogent Biosciences (COGT) has 4 years of Non-cash Items data on record, last reported at $42.6 million in Q3 2021.

  • For Q3 2021, Non-cash Items changed N/A year-over-year to $42.6 million; the TTM value through Sep 2021 reached $42.6 million, changed N/A, while the annual FY2020 figure was $3.8 million, 1070.4% up from the prior year.
  • Non-cash Items reached $42.6 million in Q3 2021 per COGT's latest filing, down from $43.7 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $43.7 million in Q2 2021 and bottomed at $321000.0 in Q4 2019.
  • Average Non-cash Items over 4 years is $20.0 million, with a median of $14.8 million recorded in 2018.
  • Peak YoY movement for Non-cash Items: plummeted 93.6% in 2019, then skyrocketed 1070.4% in 2020.
  • A 4-year view of Non-cash Items shows it stood at $5.0 million in 2018, then tumbled by 93.6% to $321000.0 in 2019, then surged by 1070.4% to $3.8 million in 2020, then soared by 1033.88% to $42.6 million in 2021.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $42.6 million in Q3 2021, $43.7 million in Q2 2021, and $24.5 million in Q1 2021.